Results 241 to 250 of about 27,102 (328)

Mortality Risk of Hypnotics: Strengths and Limits of Evidence

Drug Safety, 2016
D. Kripke
semanticscholar   +1 more source

Is Addiction Research Addicted to Artificial Intelligence? Mapping the Intersection of Artificial Intelligence, Substance Use and Mental Health Through a Bibliometric Analysis

Drug and Alcohol Review, Volume 45, Issue 1, January 2026.
ABSTRACT Issues From extracting insights from large‐scale, multimodal data to prevention and support, there is growing interest in the applications and implications of recent advances in Artificial Intelligence (AI) within the fields of addiction, substance use and mental health, which we refer to as ASUM.
Loïs Vanhée, Simone Scarpa
wiley   +1 more source

Psychotropic dose equivalence in Japan

Psychiatry and Clinical Neurosciences, 2015
T. Inada, A. Inagaki
semanticscholar   +1 more source

The Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction—A Narrative Review

Drug and Alcohol Review, Volume 45, Issue 1, January 2026.
ABSTRACT Issues In Australia, detections of novel benzodiazepines (NBZ) and related overdoses have increased markedly over the last five years. This review summarises Australian peer‐reviewed literature and NBZ‐related drug alerts, outlines the pharmacology of commonly detected NBZs and discusses approaches to harm reduction, managing toxicity ...
Jack Freestone, Stassi Kypri, Jennifer L. Schumann, Erica Franklin, Cameron Francis, Monica J. Barratt, Amy Peacock, Rachel Sutherland, Brendan Clifford, Harriet MacDonald, Nadine Ezard, Kathryn Fletcher, Liam Acheson, Krista J. Siefried   +13 more
wiley   +1 more source

Routine flumazenil administration confounds emergence time comparisons between remimazolam and propofol: a methodological concern. [PDF]

BMC Anesthesiol
Cui H, Zeng Q, Zhang Y.
europepmc   +1 more source

Socioeconomic trends in anxiolytic, hypnotic, and sedative use among secondary school students in Spain from 2010 to 2021: a repeated cross-sectional design [PDF]

Xabi Martínez-Mendia, Unai Martín, Anna Barbuscia, Amaia Bacigalupe   +3 more
openalex   +1 more source

Risk of depression with GLP‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 197-209, January 2026.
Abstract Aims The association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and depression remains uncertain due to contradictory evidence. We compared the risk of incident depression between GLP‐1 RAs and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) in overweight or obese adults with type 2 diabetes.
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Residual Effects of Acute and Subchronic Zolpidem Treatments on Attentional Processes in Aged Female Rats

Fundamental &Clinical Pharmacology, Volume 40, Issue 1, January 2026.
ABSTRACT Rational Zolpidem, a hypnotic Z‐drug commonly prescribed to promote sleep, is predominantly used over the age of 50. In this elderly population, adverse behavioral disturbances, impaired driving performance, and an increased risk of falls have been frequently reported.
Marianne Leger, Michel Boulouard, Christophe Liet, Ben Grayson, Michael Harte, Joanna C. Neill, Marie‐Laure Bocca, Véronique Lelong‐Boulouard   +7 more
wiley   +1 more source

How does psychoactive substance use affect health students? An important local cutout. [PDF]

Brain Behav Immun Health
Sampaio GR, Silva MBL, Soares DM, Braga-de-Souza S.   +3 more
europepmc   +1 more source

Response to letter “Do all hypnotic drugs and sedatives have risk for cancer?”

, 2015
Børge Sivertsen, Paula Salo, Jaana Pentti, Mika Kivimäki, Jussi Vahtera   +4 more
openalex   +2 more sources